The pharmaceutical world is observing a major shift in diabetes management with the introduction of GLP-1 skin applications. These patches offer a seemingly more user-friendly alternative to shots of GLP-1 receptor agonists, minimizing the frequency of daily needle pricks. The technology administers the medication directly through the epidermis, ar